Clinical Trial Search

Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 321; 130 Participants — p=0.005

Primary: International Restless Legs Syndrome Rating Scale (IRLS) Total Score — -11.6; -14.3; -14.6 Scores on a scale

Primary: Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33) — 2.157; 1.969 g/dL

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned) — 72.8; 74.3 percentage of…

Primary: Time From Randomization to the Occurrence of a Bipolar Event (TOBE) — 50; 155; 120; 163 Days — p=0.0717

Primary: Pain Intensity — 0.3; 0.4 units on a scale

Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 — -0.67; -0.79 Percentage of HbA1c in the blood — p=0.0086

Primary: The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) — 79.5; 50 Percentage of participants…

Primary: Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B) — 90.3…

Primary: Number of Participants Who Seroconvert to Human Papillomavirus (HPV) Type 6 — 147; 1 Participants

Primary: Disease Free Survival (DFS) — 50.5; 48.2 months — p=0.3235

Primary: Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period — 61; 22; 3; 3 participants

Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24 — -1; 5.6 Percent Change from Baseline — p=<0.0001

Primary: Change in Clinical Activity Score (CAS) — -1.2; -1.5 units on a scale — p=0.73

Primary: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale — 127; 124 Participants — p=0.8487